1h Free Analyst Time
The castration-resistant prostate cancer (CRPC) treatment market is forecasted to grow by USD 5.98 bn during 2023-2028, accelerating at a CAGR of 8.83% during the forecast period. The report on the castration-resistant prostate cancer (CRPC) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of prostate cancer, rising research and development (r and d) efforts in CRPC treatment, and increasing awareness of prostate cancer diagnosis.
The castration-resistant prostate cancer (CRPC) treatment market is segmented as below:
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Therapy
- Hormonal therapy
- Chemotherapy
- Others
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the castration-resistant prostate cancer (CRPC) treatment market covers the following areas:
- Castration-resistant prostate cancer (CRPC) treatment market sizing
- Castration-resistant prostate cancer (CRPC) treatment market forecast
- Castration-resistant prostate cancer (CRPC) treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global castration-resistant prostate cancer (CRPC) treatment market: Active Biotech AB, Allarity Therapeutics Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Everest Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, Medias Klinikum GmbH and Co. KG, Merck KGaA, Novartis AG, Pfizer Inc., Robotic Prostate Centre Cambridge, Sanofi SA, The Focal Therapy Clinic, and Ono Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is evolving CRPC treatment options.'
According to the report, one of the major drivers for this market is the increasing prevalence of prostate cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Active Biotech AB
- Allarity Therapeutics Inc.
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Bayer AG
- BeiGene Ltd.
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Everest Pharmaceuticals Ltd.
- F. Hoffmann La Roche Ltd.
- Johnson and Johnson
- Medias Klinikum GmbH and Co. KG
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Robotic Prostate Centre Cambridge
- Sanofi SA
- The Focal Therapy Clinic
- Ono Pharmaceutical Co. Ltd.